Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer

BACKGROUND: In patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC), the role of maintenance therapy after first-line treatment with chemotherapy plus antiepidermal growth factor receptor (EGFR) monoclonal antibodies (MoAb) is still an object of debate. METHODS: We assessed the effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Cardone, Claudia, Martinelli, Erika, Troiani, Teresa, Sforza, Vincenzo, Avallone, Antonio, Nappi, Anna, Montesarchio, Vincenzo, Andreozzi, Francesca, Biglietto, Maria, Calabrese, Filomena, Bordonaro, Roberto, Cordio, Stefano, Bregni, Giacomo, Febbraro, Antonio, Garcia-Carbonero, Rocio, Feliu, Jaime, Cervantes, Andrés, Ciardiello, Fortunato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735666/
https://www.ncbi.nlm.nih.gov/pubmed/31555481
http://dx.doi.org/10.1136/esmoopen-2019-000519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735666/
https://www.ncbi.nlm.nih.gov/pubmed/31555481
http://dx.doi.org/10.1136/esmoopen-2019-000519

Ejemplares similares